Kura Oncology
Update in progressKURA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Its lead product, KOMZIFTI (ziftomenib), is a potent, selective, oral menin inhibitor. Darlifarnib is part of the Phase 1 FIT-001 program, evaluating darlifarnib in combination with other targeted therapies across multiple solid tumors. KO-7246 is a next-generation menin inhibitor explored for diabetes and cardiometabolic disorders and as a combo partner in solid tumors. Headquartered in San Diego, California.
Company score
- Sentiment
- 0.47
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.34
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Troy Edward Wilson J.D., Ph.D.
- Employees260
- Websitekuraoncology.com
Identifiers
- ISINUS50127T1097
- FIGIBBG008974342
- LEI5493005QORQTZCZYOP39
- CUSIP50127T109
- CIK0001422143